US · Healthcare · Biotechnology
EPS came in at -0.18 against a street estimate of -0.17 — a miss of 5.9%.
Analysts rate Abcellera Biologics Inc a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $17.12.
CONFIDENT ABCL635 Phase II hot flashes data imminent; expects positive readout enabling late-stage trials. Two major TCE partnerships (Vertex, Jazz) worth $110M+ upfront, $4B+ total potential. Strong cash position $567M supports 3+ years funding. Q2 2026 No geographic segment breakdown provided. Analysts probed ABCL635 efficacy benchmarks, Phase III design rationale, and TCE resource allocation. Management deferred Phase III design details pending data readout, emphasized menopause contraindication market (>1M women) plus cancer VMS opportunity, and confirmed GPCR/ion channel remains higher priority than TCE by headcount. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 9.34% |
| Capital World Investors | 4.19% |
| Two Sigma Investments LLC | 3.26% |
| TD Waterhouse Canada Inc | 2.95% |
| UBS Asset Mgmt Americas Inc | 2.34% |
| UBS Group AG | 1.30% |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 1.27% |
| BlackRock Inc | 1.25% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 ABCELLERA BIOLOGICS INC. - 8-K SUMMARY HEADLINE NUMBERS • Company conducted underwritten public offering on August 12, 2026 • Offering size: 17,435, | 2026-08-13 |
| Reg FD disclosure · Q3 2026 ABCELLERA BIOLOGICS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced positive top-line results from Phase 2 portion of Phase 1/2 clinica | 2026-08-10 |
| Company announcement · Q3 2026 ABCELLERA BIOLOGICS INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • Company: AbCellera Biologics Inc. (Ticker: ABCL, listed on Nasdaq) • Headquarters: Va | 2026-08-07 |
| Quarterly report · Q2 2026 ABCELLERA BIOLOGICS INC. – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total assets: $1,307.6 million as of June 30, 2026 (down from $1,357.0 milli | 2026-08-05 |
| Results announced · Q3 2026 ABCELLERA Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net loss: $55.4 million in Q2 2026 vs. $34.7 million in Q2 2025 (59% increase) • Loss per shar | 2026-08-05 |
| Quarterly report · Q1 2026 ABCELLERA BIOLOGICS INC. — Q1 2026 SUMMARY HEADLINE NUMBERS • Total Revenue (Q1 2026): $8.3 million (up from $4.2 million in Q1 2025) - Research f | 2026-05-11 |
| Proxy statement · Q4 2025 ABCELLERA BIOLOGICS INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class III directors—John S. Montalba | 2026-04-29 |
| Annual report FY2025 ABCELLERA BIOLOGICS INC. - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market Capitalization (as of June 30, 2025): approximately $789.2 mi | 2026-02-24 |
Readable in the app.
| Announcement | Date |
|---|---|
| Collaboration with Vertex to research and develop multispecific T-cell engagers AbCellera Biologics announced a collaboration with Vertex Pharmaceuticals on July 29, 2026, to jointly research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) | 2026-07-29 |
| Preclinical research collaboration and option license agreement for T-cell antibodies AbCellera Biologics announced a preclinical research collaboration, option and license agreement on June 17, 2026, to discover and develop next-generation T-cell engaging (TCE) multispecific | 2026-06-17 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Abcellera Biologics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.